Revealing Results of Phase Three Randomized NETTER-2 Novartis Trial to Explore a First Line Treatment for NET
Time: 9:15 am
day: Conference Day One
Details:
- To discuss the results of the NETTER 2 clinical trial
- To review the current use of RLT in first line treatment of cancer
- To understand the role of RLT in aggressive NET disease
